The t(11; 22)(p13; q12) translocation associated with desmosplastic small round cell tumor results in a chimeric molecule fusing the amino terminal domain (NTD) of the EWS1 gene to three of the four carboxyterminal zinc ®ngers of the WT1 tumor suppressor gene. Since the DNA binding domains of WT1 and EWS/WT1 are structurally dierent, we have assessed the functional consequences of the EWS/WT1 fusion. We ®nd that the EWS/WT1 protein has a higher binding anity for a given recognition target than the WT1 product. This is unlike other fusion products involving translocation of the NTD of EWS to DNA binding domains in which DNA binding speci®city and anity is not changed. We demonstrate that EWS/WT1 is a nuclear protein and that the NTD of EWS contains (a) nuclear localization signal(s). We also ®nd that the integrity of a domain within the WT1 zinc ®ngers, responsible for mediating interaction between WT1 and the transcriptional repressor par-4, is disrupted in the EWS/WT1 fusion product. Deletion analysis of the NTD of EWS indicated that integrity of the entire domain was necessary to achieve full transactivation potential.
Introduction
Desmoplastic Small Round Cell Tumor (DSRCT) is an aggressive, rare tumor that generally occurs in adolescent males and is located to the peritoneal surfaces of the abdomen. A striking feature of this tumor is multilineage dierentiation, showing epithelial, neural, and myogenic immunophenotypes (Gerald et al., 1991) . This malignancy is associated with a recurrent translocation t(11;22)(p13;q12), which fuses the N-terminal domain (NTD) of the EWS1 gene in frame to three of the four C-terminal zinc ®ngers of the WT1 tumor suppressor gene (Ladanyi and Gerald, 1994; Gerald et al., 1995) . The EWS1 gene is involved in several tumor-related chromosomal translocations that produce fusions with genes postulated to function as transcription factors (Ladanyi, 1995) . In each case, the translocation produces chimeric molecules containing the NTD of EWS1 (EWS-NTD) fused to the DNA binding domain of the partner. The EWS1 gene encodes a 656 amino acid protein that contains three arginine-and glycine-rich tracts and an 85 amino acid RNA recognition motif at its C-terminus. The NTD (aa 1 ± 285) of EWS1 is composed almost exclusively (*90%) of tyrosine, glutamine, glycine, alanine, serine, threonine, and proline residues organized in a repeated and degenerated polypeptide motif having the consensus, NSYGQQS. This domain shares distant homology to the C-terminal region of eukaryotic RNA polymerase II.
The Wilms' tumor gene, WT1, encodes a zinc-®nger transcription factor belonging to the EGR (early growth response) family of Cys 2 -His 2 zinc ®nger proteins and is mutated in 5 ± 15% of sporadic WTs (Reddy and Licht, 1996) . The pre-mRNA is alternatively spliced at two coding exons to produce four WT1 polypeptide isoforms containing four zinc ®ngers (Haber et al., 1991) . The second alternative splice site inserts (+) or removes (7) 3 amino acids, (+) KTS, between zinc ®ngers III and IV and alters the DNA binding speci®city of the protein (Rauscher et al., 1990) . The WT1 isoforms recognize the GC-rich motif, 5'-GCGGGGGCG-3', as well as a (TCC) n motif, albeit with dierent anities, and can aect expression of a number of genes involved in the regulation of cell proliferation or dierentiation (Reddy and Licht, 1996; Rauscher et al., 1990; Wang et al., 1993) . These include insulin-like growth factor II, insulin-like growth factor 1 receptor (IGF-IR), platelet-derived growth factor Achain, colony stimulating factor-1, transforming growth factor-b1, retinoic acid receptor-a, Pax-2, c-myb, epidermal growth factor receptor, bcl-2, c-myc, syndecan-1, and the WT1 gene itself (Reddy and Licht, 1996) .
In comparison to WT1, little is known about the functional properties of the EWS/WT1 gene product. A truncation polypeptide containing only 21 EWS amino acids fused to WT1 zinc ®ngers II-IV is still capable of binding to WT1 DNA recognition elements . In contrast to WT1, which inhibits transcription of the IGF-IR gene, EWS/WT1 activates transcription from this promoter (Karnieli et al., 1996) . Therefore, deregulation of WT1 downstream targets by EWS/WT1 may play a role in transformation. In this report, we demonstrate that the DNA binding domains of WT1 and EWS/WT1 are functionally distinct, providing a molecular understanding into some of the functional dierences between the WT1 tumor suppressor gene and the EWS/WT1 oncogene. from an in-frame junction of EWS1 exons 1 ± 7 to WT1 exons 8 ± 10 (Figure 1 ) (Ladanyi and Gerald, 1994; Gerald et al., 1995) . This chimeric gene encodes a protein in which the RNA-binding domain of EWS1 is replaced by three C-terminal zinc ®ngers of the WT1 DNA-binding domain. Since WT1 exon 9 is alternatively spliced (+KTS), two EWS/WT1 mRNA isoforms (+KTS) are also produced (Gerald et al., 1995) . Previous studies on WT1 DNA sequence recognition speci®city have demonstrated that loss of WT1 zinc ®nger I can result in a mutant polypeptide with reduced DNA binding properties (Nakagama et al., 1995; Drummond et al., 1994) . However, EMSA performed with a recombinant protein consisting of only 21 amino acids from EWS1 fused to WT1 zinc ®ngers II-IV, suggested that loss of the ®rst zinc ®nger, in the context of 21 EWS amino acids, increased DNA binding . In light of experiments suggesting that the NTD of WT1 may in¯uence its DNA binding anity (Nakagama et al., 1995) , we de®ned the DNA binding properties of the full-length EWS/WT1 fusion products. Synthetic RNAs produced by in vitro transcription of full-length EWS-WT1 (+KTS) and EWS/WT1 (7KTS) isoform were used to program cell-free rabbit reticulocyte lysate translation reactions. The 35 S-methionine-labeled protein products were visualized by SDS-polyacrylamide gel electrophoresis (Figure 2a ). For reasons not completely understood, but which may be related to the nature of the NSYGQQS repeat and/or the presence of 31 prolines within the NTD-EWS domain, the estimated molecular masses of the EWS/WT1(+KTS) proteins produced in vitro were *50 ± 55 kDa, slightly larger than the predicted molecular masses of *40 kDa (Figure 2a) . The same phenomenon has been noticed with EWS/ATF1 fusions, which also have an apparent molecular mass greater than predicted (Brown et al., 1995) . To determine if our recombinant proteins were functional, we performed EMSA with both EWS/WT1 isoforms using an oligonucleotide containing three WT1 binding sites (Figure 2b ). Our results demonstrate that only EWS/WT1 (7KTS) could form complexes with the WT1 binding site probe ( Figure  2b , compare lanes 7 ± 10 to lanes 2 ± 5). These results indicate that the binding speci®cites of the EWS/WT1 (+KTS) isoforms resemble those previously de®ned for the WT1 isoforms.
EMSAs were performed with in vitro generated full length WT1(+/7) and EWS/WT1(7KTS) under conditions where WT1 binding site probe concentration (WTE: 5'-gagtGCGTGGGAGTagaa-3') was kept constant, and the amount of input protein varied ( Figure 3 ). One speci®c complex formed with EWS/ WT1(7KTS), whereas two speci®c complexes were observed in reaction mixtures containing WT1(+/7) protein (compare lanes 2 to 6 to lanes 7 to 11, Figure  2a ). All indicated complexes (see arrows, Figure 3a ) were speci®c since they could be competed with excess unlabeled oligonucleotide containing the WTE sequence (JK and JP, data not shown). The faster migrating complex (complex II) observed with WT1 has been previously noted and is thought to arise from a truncated version of WT1 generated by leaky scanning and translation initiation at a downstream (Nakagama et al., 1995) . To quantitate the binding anities, we performed equilibrium DNA binding analysis to achieve saturation of the WTE site with recombinant protein synthesized in vitro (Figure 3b ). The intensity of the complexes increased proportionally with the amount of protein added to the reaction mixture. A bound/free probe ratio of 0.5 was achieved with 0.2 ml of normalized EWS/WT1 (7KTS) and 1.2 ml of normalized WT1(+/7) lysate, clearly demonstrating that protein/DNA complex formation is saturating at lower concentrations of EWS/WT1 (7KTS) compared to WT1(+/7). Each experiment was performed at least three times, yielding reproducible binding anities.
EMSAs were performed in the presence of excess probe, ranging from 0.23 nM to 13 nM, to evaluate the dissociation constants (Figure 3c ). The dissociation constant (K d calculated by Scatchard plot analysis) of the WT1 binding sequence was 0.34 nM for EWS/ WT1(7KTS) and 4.7 nM for WT1(+/7). These results clearly indicate that substitution of the NTD of WT1 and the WT1 ®rst zinc ®nger, by the NTD-EWS, creates a fusion product with higher DNA binding anity.
The NTD-EWS harbors a nuclear localization signal
Since the NTD-EWS is usually tethered to RNA (via the RBD), we wished to establish the subcellular localization of the EWS/WT1(+KTS) isoforms by indirect immuno¯uorescence (Figure 4) . We have previously shown that WT1 zinc ®ngers II and III harbor a nuclear localization signal (Bruening et al., 1996) . Therefore, one consequence of fusing the NTD-EWS to WT1 zinc ®ngers II-IV should be nuclear targeting. It is formally possible that the sequencespeci®c binding of WT1 zinc ®ngers II-IV are not required for transformation by EWS/WT1 (+KTS), but rather serve only to provide a nuclear localization function. COS-7 cells were transfected with either an empty pcDNA3 expression vector (Figure 4a ), pcDNA3-EWS/WT1 (+KTS) (Figure 4b ), or pcDNA3-EWS/WT1 (7KTS) (Figure 4c ) and processed for immuno¯uorescence. Our results formally indicate that both EWS/WT1 isoforms localize to nuclei, as predicted. To determine whether the NTD-EWS harbored a nuclear localization signal, independent of the one present in the WT1 zinc ®ngers, we constructed a C-terminal HA-tagged EWS(NTD) expression vector lacking the 3 WT1 zinc ®ngers. Surprisingly, indirect immunohistochemistry revealed that the HA tagged EWS(NTD) could also localize to the nucleus (Figure 4d ). Since polypeptides having molecular masses less than 40 ± 50 kDa can passively diuse into the nucleus (Breeuwer and Goldfard, 1990) , and the EWS(NTD) product was *30 kDa, we wished to exclude this possibility. We therefore constructed a b-galactosidase/EWS(NTD) fusion, with an estimated molecular mass of *150 kDa. When introduced into COS-7 cells, the b-galactosidase/ EWS(NTD) product localized to the nucleus ( Figure  4e ). Since b-galatosidase is cytoplasmic when introduced into eukaryotic cells, these results demonstrate that the NTD-EWS harbors a nuclear localization domain. Thus, the WT1 zinc ®ngers likely contribute more than simply nuclear localization to the transformation potential of the EWS/WT1 isoforms, since this property is also present within the NTD-EWS. 
EWS/WT1 isoforms are defective for par-4 binding
The WT1 tumor suppressor gene product interacts with par (prostate apoptosis response)-4 (Johnstone et al., 1996) , a polypeptide that also functions independently as a transcriptional repressor and whose expression is upregulated during apoptosis of prostate cells (Sells et al., 1994) . This interaction is mediated via the leucine repeat domain of par-4 and the zinc ®nger DNA binding domain of WT1 (Johnstone et al., 1996) . Par-4 modulates WT1 activity by inhibiting WT1-mediated transcriptional activation and augmenting WT1-mediated repression (Johnstone et al., 1996) . To assess if par-4 could interact with EWS/WT1 fusion products,
free probe 1 2 3 4 5 6 7 8 9 10 11 b c Figure 3 Relative anities of EWS/WT1 (7KTS) and WT1 (+/7) for the WTE recognition motif. (a) EMSA comparing the relative anities of EWS/WT1 (7KTS) and WT1 (+/7). Following in vitro translations, protein concentrations were normalized and used in gel shift assays as described in the Materials and methods. A radiolabeled probe, containing one WT1 recognition motif, was incubated with either unprogrammed reticulocyte lysate (lane 1), reticulocyte lysate programmed with EWS/WT1 (7KTS) mRNA (lane 2, 0.1 ml; lane 3, 0.5 ml; lane 4, 0.8 ml; lane 5, 1.0 ml; lane 6, 5.0 ml of lysate), or reticulocyte lysate programmed with WT1 (+/7) mRNA (lane 7, 0.1 ml; lane 8, 0.5 ml; lane 9, 0.8 ml; lane 10, 1.0 ml; lane 11, 5.0 ml). Protein concentrations were normalized such that equal moles of EWS/WT1(7KTS) or WT1(+/7) were present in the same volumes added to the EMSA. For all reactions, the total amount of the lysate was adjusted to 5.0 ml with unprimed control lysate. EMSAs were performed with 2.3 nM of oligonucleotide as probe. Speci®c complexes and the free probe are indicated by arrows. (b) Graphical representation comparing the binding properties of increasing amounts of EWS/WT1 (7KTS) or WT1(+/7) for the WTE site. The y-axis indicates the amount of radiolabeled oligonucleotide present in a speci®c protein/DNA complex relative to the total amount of input probe, expressed as a percent. The x-axis represents the amount of input translation product, normalized so that each point contains equivalent moles of protein. a series of anity selections were performed ( Figure 5 ). Radiolabeled WT1 could speci®cally bind to GST/par-4 ( Figure 5 , lane 3), but not GST alone (lane 2), as previously reported (Ladanyi and Gerald, 1994) . In contrast, neither EWS/WT1 isoform could associate with par-4 (compare lanes 6 and 9 to lanes 5 and 8, respectively), indicating that par-4/WT1 zinc ®nger interaction is not faithfully maintained in the EWS/ WT1 fusion products.
Transactivation potential of the NTD-EWS
The WT1 NTD generally functions as a transcriptional repressor (Reddy and Licht, 1996) , whereas the EWS1/ WT1 fusion appears to function as a transcriptional activator Karnieli et al., 1996) . Thus, the NTD-EWS appears to contribute to the transcriptional activation function of EWS/WT1 by providing a novel activation domain. To assess the transcriptional eects of the NTD-EWS, expression vectors containing GAL4-EWS fusions were generated (Figure 6a ). The reporter plasmid contained the E1B minimal promoter with 5' upstream GAL4 binding sites (Figure 6a S-Met labeled protein (lanes 1, 4, and 7), as well as the pellet from the GST pull-down (lanes 2, 5, and 8), or the pellet from the GST/par-4 pull-down (lanes 3, 6, and 9) were analysed on an 10% SDS ± PAGE and proteins were visualized bȳ uorography. Recombinant proteins used were 35 S-labeled WT1(+/7) (lanes 1 ± 3), EWS/WT1 (+KTS) (lanes 4 ± 6), and EWS/WT1 (7KTS) (lanes 7 ± 9). Note that the WT1 (+/7) product in lane 3 is artifactually migrating slightly faster than the same product in lane 1, because of the presence of unlabeled GST/par-4 in lane 3, migrating just above the WT1(+/7) product and causing a slight compression GAL4 recognition domain produced a polypeptide no longer capable of activating (56Gal4)E1B/CAT (compare lane 5 to 4). Co-transfection of GAL4-EWS(NTD) with an E1B/CAT vector lacking GAL4 binding sites did not produce an increase in CAT expression (JK and JP, data not shown). These results are consistent with the presence of an activation domain within the NTD-EWS.
The amino acid sequence of EWS does not suggest any particular discrete region that might be important for transcriptional activation. Therefore, a series of deletions were generated within the NTD-EWS to de®ne such a region (Figure 6c ). Deletion of NTD ± EWS amino acids 246 ± 265 [GAL4-EWS(1 ± 245)] produced a polypeptide with reduced transactivation abilities relative to GAL4-EWS(NTD) (Figure 6c) . Removal of additional amino acids from the C-terminus of NTD ± EWS [GAL4-EWS(1 ± 163)] further reduced the transactivation properties. Plasmid GAL4-EWS(1 ± 182) produced a polypeptide with only 2% the transactivation potential of the polypeptide produced by GAL4-EWS(NTD). Plasmids GAL4-EWS(1 ± 35) and GAL4-EWS(1 ± 13) demonstrated signi®cantly reduced transactivation potential, relative to GAL4-EWS(NTD). Transcriptional activation was also impaired with the product of GAL4-EWS(13 ± 265), a deletion removing amino acids 1 ± 12 from the N-terminus of EWS1. Construct GAL4-EWS(118 ± 265) demonstrated that a progressive N-terminal deletion further impaired transactivation, as did a deletion mutant in which the N-and C-termini had been slightly truncated [GAL4-EWS(13 ± 245)]. Plasmid GAL4-EWS(D82 ± 175), containing an internal deletion which removes amino acid 83 ± 174, failed to activate reporter gene expression. Dierences in transactivation potential among the various NTD-EWS deletion mutants are not due to dierences in protein amounts since Western blot analysis revealed equivalent amounts of protein produced from each construct (JK and JP, data not shown). We interprete these results to indicate that the overall integrity of the NTD-EWS domain is necessary for its full transactivation potential.
Discussion
Molecular characterization of speci®c chromosomal translocations associated with human tumors had led to the discovery of new mechanisms involved in neoplastic transformation (Rabbitts, 1994) . The EWS1 gene is found to be translocated in a wide variety of human solid tumors. In each translocation case involving EWS1, the chimeric product contains the NTD-EWS juxtaposed next to the DNA binding domain of a transcription factor. The fusion partners involve: (i) the ETS-related DNA binding domain of FLI1, ERG, or ETV1 in Ewing's sarcoma and related primitive neuroectodermal family of tumors (Delattre et al., 1992; Sorensen et al., 1994; Jeon et al., 1995) , (ii) the bZIP protein dimerization and DNA binding domain of ATF-1 in clear-cell sarcoma of soft tissue (Zucman et al., 1993) , and (iii) three of the four WT1 zinc ®ngers in DSRCT (Ladanyi and Gerald, 1994; Gerald et al., 1995) .
Fusion of the NTD-EWS to novel DNA binding domains creates chimeric proteins with altered DNA speci®city and transactivation potential. EWS/FLI1, EWS/ERG, EWS/ATF1, and EWS/WT1 have all been shown to be potent transcriptional transactivators Karnieli et al., 1996; Brown et al., 1995; Ohno et al., 1993 Ohno et al., , 1994 Bailly et al., 1994; May et al., 1993b) . EWS1 shares signi®cant sequence homology to TLS (*55% identity), a gene involved in a translocation in human myxoid liposarcoma (Crozat et al., 1993) , as well as to the TATA-binding proteinassociated factor-68 (TAF II 68) (59% identity) (Bertolotti et al., 1996) . The sequence similarity shared among these proteins suggest that the TLS and EWS1 gene products may also be present in TFIID complexes, a scenario which has been experimentally veri®ed in the case of TLS (Bertolotti et al., 1996) . Hence NTD-EWS may stimulate transcription in a fashion similar to that proposed for TAF II 68, by Thin layer chromatography analysis of cell extracts was performed as previously described (Gorman, 1985) . Cm indicates Previous studies suggested that the NTD-EWS can activate directly (Brown et al., 1995; Ohno et al., 1993; May et al., 1993b) or via allosteric regulation of an activation domain present in the fusion partner (Ohno et al., 1993 (Ohno et al., , 1994 . In the case of EWS/FLI1 and EWS/ ERG fusions, removal of the entire NTD-EWS produced chimeric proteins with signi®cant residual transactivation potential, indicating that at least two transactivation domains are present in these chimeric molecules ± one within the NTD-EWS and one within the translocated DNA binding domain (Ohno et al., 1993 (Ohno et al., , 1994 . In order to better de®ne the transactivation potential of the NTD-EWS, we fused this domain to a non-physiologically relevant DNA-binding domain (GAL4), which on its own does not have residual transactivation potential ( Figure 6 ). This GAL4/EWS chimeria was capable of transcriptional activation ( Figure 6 ). Note that the activation potential of NTD ± EWS is *50-fold lower than that of VP16 (J.K. and J.P., unpublished data). Our deletion analysis of the NTD-EWS demonstrated that the entire NTD (aa 1 ± 265) is required for full transactivation potential since amino-or carboxyl-terminal deletions reduced this activity (Figure 6 ). We concluded that the overall nature or structure of the NTD contributes to the transactivation potential of EWS and this may directly relate to the total number of NSYGQQS motifs. If the NTD-EWS interacts with RNA PolII, as does TAF II 68 (Bertolotti et al., 1996) , then the stringency of this interaction may be in¯uenced by the total number of NSYGQQS motifs and determine transactivation potential. Alternatively, the putative interaction with RNA PolII may not be possible in the EWS chimeric fusions, and the fusion products may aect transcription via alternative mechanisms.
Fusion of WT1 zinc ®ngers II-IV to the NTD-EWS generates a fusion product with DNA binding properties quite distinct from those of the WT1 tumor suppressor gene (Figures 2, 3 and 5) . The WT1 tumor suppressor gene product contains four zinc ®ngers, with zinc ®ngers II-IV showing a high degree of similarity to the three EGR (early growth response)-1 zinc ®ngers (Call et al., 1990; Gessler et al., 1990) . Since physiological targets of EWS/WT1 are only beginning to be evaluated (Karnieli et al., 1996) , we cannot exclude the possibility that EWS/WT1 may even bind a sequence not recognized by WT1. Previous EWS/WT1 EMSA have been performed with bacterially produced recombinant proteins, containing only 21-EWS encoded amino acids and have failed to evaluate binding anities or consider potential contributions from the NTD-EWS to DNA binding . Our results, utilizing full-length EWS/WT1 fusions, clearly show that EWS/WT1 has a higher binding anity (*tenfold) for a given WT1 recognition element, compared to WT1 (Figures 2 and 3) . Although dissociation constants have not been measured for other EWS fusion products and their DNA targets, EWS/FLI1 binds to DNA sequences indistinguishable from those bound by FLI1 (Bailly et al., 1994; Mao et al., 1994) . It would seem that enhanced DNA binding is a situation which appears to be unique to the EWS/WT1 (7KTS) fusion product. In addition, there is a clear functional dierence in DNA binding between EWS/WT1(7KTS) and EWS/WT1 (+KTS) isoforms (Figure 2) , similar to what has been reported for WT1 (+KTS) isoforms (Reddy and Licht, 1996) . WT1 zinc ®nger I appears to play a clear role in WT1 DNA recognition. Deletion of this ®nger, or site-directed mutagenesis aecting residues predicted to chelate zinc, decreases the eciency of WT1/DNA complex formation (Nakagama et al., 1995) . The importance of this ®nger to WT1 biology is underscored by the identification of a germline missense mutation aecting a cysteine residue (and presumably Zn 2+ binding) associated with Denys-Drash syndrome, a developmental disorder resulting in abnormal urogenital system development and predisposition to Wilms' tumors (Bruening et al., 1992) . Studies on the contribution to sequence recognition by Drummond et al. (1994) suggest that zinc ®nger I contributes signi®cantly to binding speci®city. Thus, not only would EWS/WT1 fusions be predicted to activate downstream targets of WT1, but activation of downstream targets of EGR-1 (or other zinc ®nger proteins), could conceivably also contribute to the oncogenic potential of EWS/WT1.
The fusion of the EWS domain to a series of DNA binding domains could be necessary to impart a nuclear localization property to EWS/WT1. We have experimentally addressed this issue by demonstrating that the NTD-EWS harbors a separate nuclear localization signal (Figure 4 ). As such EWS/WT1 fusion products contain at least two nuclear localization signals, one with the NTD-EWS and one within zinc ®ngers II-III (Bruening et al., 1996) . These results formally demonstrate that EWS/WT1(+KTS) isoforms are nulcear proteins.
The WT1 zinc ®ngers are not only required for nucleic acid recognition, but also harbor a dimerization motif responsible for mediating association with par-4, a transcriptional repressor (Johnstone et al., 1996) . Par-4 functions to modulate WT1 transcriptional properties such that (i) it augments WT1-mediated repression (possibly by contributing an additional repression domain) and (ii) it inhibits WT1-mediated transactivation (Johnstone et al., 1996) . The par-4 gene is transcriptionally induced by apoptotic signals in the prostate (Sells et al., 1994) , and may act to sensitize cells to apoptotic signals (unpublished data cited by Johnstone et al., 1996) . In this report, we demonstrate that par-4 interaction is not faithfully maintained with either EWS/WT1 (+KTS) or EWS/WT1(7KTS) isoforms ( Figure 5 ). These results have two implications: (i) they argue that the integrity of WT1 zinc ®nger I is essential in maintaining par-4 interaction, and (ii) the abolishment of par-4 binding to EWS/WT1 may contribute to the oncogenic potential of this fusion product, since par-4 binding to EWS/WT1 could be expected to prevent activation by the NTD-EWS domain. The p53 gene product can also associate with WT1 via its zinc ®ngers (Maheswaran et al., 1995) . We have not assessed whether this association is maintained with EWS/WT1 chimeric products, but its disruption could also be important to the mechanism of transformation by EWS/WT1.
Unlike EWS/FLI1 and EWS/ERG which can transform NIH3T3 cells (May et al., 1993a,b; Ouchida et al., 1995) , the predicted transforming activity of EWS/WT1 has yet to be demonstrated. How might EWS/WT1 contribute to the malignant process in DSRCT? In light of our characterization of the EWS/ WT1 DNA binding domain, there are several possibilities. (i) DNA binding anity for some WT1 targets is increased hence deregulation of WT1 targets may occur in cells expressing EWS/WT1. WT1 transcripts have been detected in DSRCTs by RT ± PCR sampling (Gerald et al., 1995) , indicating that the WT1 promoter is transcriptionally active in these cells. Since WT1 is generally a transcriptional repressor, competition between WT1 and EWS/WT1 for common targets would produce a situation in which expression of the targets would be deregulated, as recently demonstrated for the IGF-1R promoter (Karnieli et al., 1996) . Additionally, since WT1 and EGR-1 recognize a common DNA sequence, EWS/WT1 may also compete for EGR-1 (or other zinc ®nger protein) targets.
(ii) The function of WT1 zinc ®ngers II-IV does not seem to be a passive one, restricted to nuclear targeting of the EWS domain. (iii) Par-4 interaction is disrupted in EWS/WT1. It is dicult to predict the functional signi®cance of this ®nding, but since par-4 harbors an independent repression domain, its loss may be necessary to EWS/WT1 transformation since it could potentially act to inhibit the activation potential of EWS/WT1, as has been demonstrated for WT1 (Johnstone et al., 1996) . It would be interesting to attempt to reconstitute par-4 binding to determine if this could prevent activation (and possibly transformation) by EWS/WT1. .
Materials and methods

General methods and materials
Plasmid construction
EWS/WT1(+KTS) cDNAs were generated by amplification of the respective domains using the polymerase chain reaction (PCR) followed by splicing of the regions using the overlap extension method (Clarkson et al., 1992) . The primary PCRs were performed with primer EW1, 5'-GAATTCATGGCGTCCACGGATTAC-3', and primer EW2, 5'-ATGGTTTCTCACTCTGCTGCCCGTAGCT-GC-3' for generating the NTD using an EWS cDNA as template. Primers EW3, 5'-ACGGGCAGCAGAGTGA-GAAACCATA-3', and EW4, 5'-AAGCTTTCAAAGCGC-CACGTGGAG-3', were used to construct WT1 zinc ®ngers II-IV of EWS/WT1 using WT1(+KTS) cDNAs as templates. The secondary PCR for generating EWS/ WT1(+KTS) cDNAs were performed using gel puri®ed primary PCR products as templates and primers EW1 and EW4. Both chimeric EWS/WT1(+KTS) PCR products were cloned in the EcoRI and HindIII sites of pBluescript II KS+ (Stratagene), and named pKSII-EWS/WT1 (+KTS). For expression in mammalian cells, an EcoRI ± XhoI fragment containing full-length EWS/ WT1(+KTS) was isolated from pKSII-EWS/ WT1(+KTS) and cloned into the same sites of pcDNA3 (Invitrogen). The resulting constructs were named pcDNA3-EWS/WT1(+KTS). For immunohistochemistry, a haemaglutinin (HA) epitope tagged EWS(NTD) was produced by PCR using primer EW1, and an HA-tagged primer, 5'-TCACAGAGGCTGCCCGTAGCTGCT-3'. All constructs involving manipulations by PCR were sequenced (Sanger et al., 1977) using double-stranded DNA templates, to ensure the absence of possible undesired mutations.
For transactivation studies, GAL4-EWS fusions were generated containing the GAL4 DNA binding domain fused to the NTD-EWS. The GAL4 DNA binding domain (aa 1 ± 147) was removed from the pGBT9 yeast two hybrid system vector (Clontech Laboratories, Inc.) using HindIII and DraI, blunted with the Klenow fragment of DNA polymerase I, and ligated to BamHI and EcoRI sites (Klenow repaired) of pKS II+ to produce pKSII/GAL4. This construct contains multiple cloning sites and termination codons in all three dierent reading frames. For generating pcDNA3/GAL4-EWS constructs, the HindIII ± XbaI fragment from pKSII/GAL4-EWS was transferred into the same sites of pcDNA3. Constructs fusing amino acid 1 to 147 of the yeast transcription factor GAL4 to various NTDs of EWS1 were constructed as follows. (a) GAL4-EWS(NTD): The NTD-EWS fragment was generated by PCR as described above, and cloned into the EcoRI ± SmaI sites of pKSII/GAL4. (b) GAL4-EWS(1 ± 245): The EcoRI ± BamHI fragment of GAL4-EWS(NTD) was ligated into pKSII/GAL4 which had been digested with the same restriction enzymes. (c) GAL4-EWS(1 ± 163): The pKSII/ EWS(NTD) cDNA was digested with AvrII, blunted with Klenow, digested with EcoRI, and the resultant fragment cloned into the EcoRI/SmaI sites of pKSII/GAL4. (d) GAL4-EWS(1-82): The pKSII/EWS(NTD) cDNA was linearized with BglI, blunted with the Klenow fragment, digested with EcoRI, and transferred into the EcoRI/SmaI sites of pKSII/GAL4. (e) GAL4-EWS(1 ± 35): The pKSII/ EWS(NTD) cDNA was digested with NdeI blunted with Klenow, re-digested with EcoRI, and transferred into the SmaI/EcoRI sites of pKSII/GAL4. (f) GAL4-EWS(1 ± 13): The pKSII/EWS(NTD) was digested with EcoRI and PstI, then cloned into the same sites of pKSII/GAL4. (g) GAL4-EWS(13 ± 264): The PstI fragment of pKSII/GAL4-EWS(NTD) was subcloned into the PstI site of pKSII/ GAL4.
(h) GAL4-EWS(118 ± 264): pKSII/GAL4-EWS(NTD) was digested with NdeI, blunted with the Klenow fragment, and re-digested with PstI. This fragment was subcloned into pKSII/GAL4. (i) GAL4-EWS(13 ± 245): The PstI fragment of pKSII/GAL4-EWS(NTD) was subcloned into the PstI site of pKSII/GAL4. (j) GAL4-EWS(D82 ± 175): The pKSII/EWS(NTD) cDNA was digested with BglI, blunted with Klenow, and digested with HindIII. The resultant fragment was ligated into pcDNA3/ GAL4-EWS which had been digested with KpnI (rendered blunt) and HindIII.
In vitro transcription and translation
In vitro transcriptions of pKSII-EWS/WT1(+KTS) were performed using T7 RNA polymerase on templates which had been linearized with SmaI. In vitro translations were performed in the presence of [
35 S]methionine in rabbit reticulocyte lysates, essentially as described by the manufacturer (Promega). For WT1(+/7) protein, SP64-based plasmid containing the WT1(+/7) gene (linearized with HindIII) were used as for in vitro transcription/ translation reactions. In vitro translation products were electrophoresed on 8% SDS ± PAGE, treated with EN 3 HANCE, dried, and exposed to Kodak X-Omat ®lm. Quantitation of radioactive products was performed by phosphoimaging scanning (Fujix BAS 2000) .
Electrophoretic mobility shift assay (EMSA)
Synthetic oligonucleotide probes for EMSAs were prepared by annealing complimentary oligonucleotides at 378C for 30 min. Annealed oligonucleotides were end labeled with g 32 P-ATP using T4 polynucleotide kinase. The binding reactions were performed in a total volume of 20 ml for 30 min at 48C in binding buer (50 mM HEPES (pH 7.5), 50 mM KCl, 5 mM MgCl 2 , 10 mM ZnSO 4 , 1 mM dithiothreitol, 20% glycerol, 1 mg of poly (dI⋅dC)⋅(dI⋅dC)) with various amounts of in vitro translated EWS/ WT1(+KTS) or WT(+/7) proteins (indicated in the respective Figures). Following binding, reaction mixtures were electrophoresed on 4% polyacryalmide gel (acrylamide/bisacrylamide ratio, 37 : 1) in 0.56TBE (44.5 mM Tris-HCl, 44.5 mM boric acid, 1 mM EDTA) buer at 150 V for 2 ± 3 h at 48C. Gels were dried and exposed to Kodak X-Omat ®lm at room temperature or to a PhosphorImager screen. For quantitative binding analysis, the intensity of the mobility shifts were quantitated by phosphorimaging analysis (Fujix BAS 2000) , and the binding anity was quantitated as the ratio of bound to unbound probe.
Quantitative analysis of equilibrium DNA binding and scatchard plot analysis
To compare the anity of EWS/WT1(7KTS) and WT1(+/7) to the WT1 DNA recognition site (WTE: 5'-gagtGCGTGGGAGTagaa-3'), we performed equilibrium DNA binding analysis using the EMSA with normalized in vitro translated EWS/WT1(7KTS) and WT1(+/7) (Figure 3) . Normalization of in vitro translated proteins were performed with 35 S-methionine labeled in vitro translation products and con®rmed with Western blotting using anti-WT1 antibodies Santa Cruz Biotechnology) . Various amounts of the EWS/WT1(7KTS) and WT1(+/7) programmed lysate were incubated with radiolabeled WTE probe and the total reaction volume adjusted by complementing with unprogrammed lysate. Samples were incubated at 48C for 30 min and analysed on a 4% polyacrylamide gel. Scatchard plot analysis was performed to determine the dissociation constant, K d , from the mobility shift assays (Scatchard, 1949) .
Cell culture, transfections and CAT assays COS-7 cell lines were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% heatinactivated fetal calf serum (Gibco BRL), penicillin, and streptomycin. For transient transfections, cells were plated at a density of 2 ± 5610 5 cells per 100 mm dish 24 h prior to transfection. Cells were transfected by the calcium phosphate precipitation method . Individual DNA precipitates were adjusted to contain equal amounts of total DNA by the addition of the empty expression vector, pcDNA3. To normalize for transfection eciency, cells were co-transfected with 2 mg of pRSV/b-gal. At 48 h after transfection, cells were harvested and assayed for b-galactosidase and CAT activity (Gorman, 1985 
